• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Psych division opening





Agreed that the job is somewhat of a joke given most every territory has three reps calling on the same providers. We sell an antipsychotic, Vraylar, where 95% of the script volume is coming from psychiatry providers yet half of our target panels are made up of bogus primary care providers that haven’t been accessible in years. So after you remove all the no see providers from the target panels there ends up being about 50-60 accessible targets in many territories. Yet our company is trying to run a sales model like it’s 2002 where you could actually see 8-10 providers a day.

2002 where you could actually see 8-10 providers a day. Smoke much dope? It hasn't been that good since the early to mid 90's FACT.